Shrestha Dhan B, Budhathoki Pravash, Subedi Prarthana, Khadka Manita, Karki Prabesh, Sedhai Yub Raj, Karki Bhesh Raj, Mir Wasey Ali Yadullahi
Department of Internal Medicine, Mount Sinai Hospital, Chicago, USA.
Department of Internal Medicine, BronxCare Health System, Bronx, USA.
Cureus. 2021 Dec 20;13(12):e20532. doi: 10.7759/cureus.20532. eCollection 2021 Dec.
Functional dyspepsia is a common gastrointestinal disorder characterized by postprandial fullness or early satiety and epigastric burning or pain in the absence of organic disease. Acotiamide is a novel prokinetic motility drug being used in functional dyspepsia. Databases like PubMed, PubMed Central, Embase, and Scopus were searched for studies comparing the use of acotiamide and placebo for people with functional dyspepsia. Quantitative synthesis was performed using RevMan 5.4 (Cochrane, London, United Kingdom). The improvement in symptoms of functional dyspepsia after treatment was higher in people treated with acotiamide than placebo, although not statistically significant (OR, 1.48; 95% CI, 0.93 to 2.35; n = 1697; I = 59%). Among the commonly reported adverse effects, namely, raised in serum prolactin (OR 1.02, 95% CI 0.64 to 1.61; n = 1709; I = 44%), raised in alanine transaminase (OR 1.27, 95% CI 0.70 to 2.33; n = 1709; I = 0%), and raised in serum bilirubin (OR, 0.98; 95% CI, 0.52 to 1.87; I = 0%) did not differ between two groups. Acotiamide seems to be a promising agent in functional dyspepsia. However, further larger studies are needed to evaluate the role of acotiamide in functional dyspepsia.
功能性消化不良是一种常见的胃肠疾病，其特征为餐后饱胀或早饱，以及在无器质性疾病情况下出现上腹部烧灼感或疼痛。阿考替胺是一种用于治疗功能性消化不良的新型促动力药物。检索了PubMed、PubMed Central、Embase和Scopus等数据库，以查找比较阿考替胺和安慰剂用于功能性消化不良患者的研究。使用RevMan 5.4（英国伦敦考科蓝协作网）进行定量合成。接受阿考替胺治疗的患者在治疗后功能性消化不良症状的改善高于接受安慰剂治疗的患者，尽管差异无统计学意义（比值比，1.48；95%置信区间，0.93至2.35；n = 1697；I² = 59%）。在常见的不良反应中，即血清催乳素升高（比值比1.02，95%置信区间0.64至1.61；n = 1709；I² = 44%）、丙氨酸转氨酶升高（比值比1.27，95%置信区间0.70至2.33；n = 1709；I² = 0%）和血清胆红素升高（比值比，0.98；95%置信区间，0.52至1.87；I² = 0%）在两组之间无差异。阿考替胺似乎是治疗功能性消化不良的一种有前景的药物。然而，需要进一步开展更大规模的研究来评估阿考替胺在功能性消化不良中的作用。
